Literature DB >> 9703523

Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.

I van Beek1, R Dwyer, G J Dore, K Luo, J M Kaldor.   

Abstract

OBJECTIVES: To estimate the incidence of HIV and hepatitis C virus and risk factors for seroconversion among a cohort of injecting drug users.
DESIGN: Retrospective cohort study.
SETTING: Primary healthcare facility in central Sydney.
SUBJECTS: Injecting drug users tested for HIV-1 antibody (n=1179) and antibodies to hepatitis C virus (n=1078) from February 1992 to October 1995. MAIN OUTCOME MEASURES: Incidence of HIV-1 and hepatitis C virus among seronegative subjects who injected drugs and underwent repeat testing. Demographic and behavioural risk factors for hepatitis seroconversion.
RESULTS: Incidence of HIV-1 among 426 initially seronegative injecting drug users was 0.17/100 person years (two seroconversions) compared with an incidence of hepatitis C virus of 20.9/100 person years (31 seroconversions) among 152 injecting drug users initially negative for hepatitis C virus. Incidence of hepatitis C virus among injecting drug users aged less than 20 years was 75.6/100 person years. Independent risk factors for hepatitis C virus seroconversion were age less than 20 years and a history of imprisonment.
CONCLUSIONS: In a setting where prevention measures have contributed to the maintenance of low prevalence and incidence of HIV-1, transmission of hepatitis C virus continues at extremely high levels, particularly among young injecting drug users.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703523      PMCID: PMC28635          DOI: 10.1136/bmj.317.7156.433

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  29 in total

1.  Hepatitis C virus in intravenous drug users.

Authors:  J Bell; R G Batey; G C Farrell; E B Crewe; A L Cunningham; K Byth
Journal:  Med J Aust       Date:  1990-09-03       Impact factor: 7.738

2.  Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam.

Authors:  J A van den Hoek; H J van Haastrecht; J Goudsmit; F de Wolf; R A Coutinho
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

3.  Viral hepatitis and drugs: a continuing problem.

Authors:  A M Patti; A L Santi; M G Pompa; C Giustini; N Vescia; I Mastroeni; G M Fara
Journal:  Int J Epidemiol       Date:  1993-02       Impact factor: 7.196

4.  Hepatitis C and the history of injecting drug use in South Australia.

Authors:  M Gaughwin; J Dodding; R Ali
Journal:  Med J Aust       Date:  1994-08-15       Impact factor: 7.738

5.  Hepatitis C virus infection in intravenous drug users: prevalence and risk factors.

Authors:  E Girardi; M Zaccarelli; G Tossini; V Puro; P Narciso; G Visco
Journal:  Scand J Infect Dis       Date:  1990

6.  Hepatitis C virus infection among a cohort of Victorian injecting drug users.

Authors:  N Crofts; J L Hopper; D S Bowden; A M Breschkin; R Milner; S A Locarnini
Journal:  Med J Aust       Date:  1993-08-16       Impact factor: 7.738

7.  Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort).

Authors:  J F Quaranta; S R Delaney; S Alleman; J P Cassuto; P Dellamonica; J P Allain
Journal:  J Med Virol       Date:  1994-01       Impact factor: 2.327

8.  Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects.

Authors:  B Galeazzi; A Tufano; E Barbierato; F Bortolotti
Journal:  Liver       Date:  1995-08

9.  Spread of bloodborne viruses among Australian prison entrants.

Authors:  N Crofts; T Stewart; P Hearne; X Y Ping; A M Breshkin; S A Locarnini
Journal:  BMJ       Date:  1995-02-04

10.  Hepatitis C and B virus infections in populations at low or high risk in Ho Chi Minh and Hanoi, Vietnam.

Authors:  S Nakata; P Song; D D Duc; X Q Nguyen; K Murata; F Tsuda; H Okamoto
Journal:  J Gastroenterol Hepatol       Date:  1994 Jul-Aug       Impact factor: 4.029

View more
  53 in total

1.  Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?

Authors:  V D Hope; A Judd; M Hickman; T Lamagni; G Hunter; G V Stimson; S Jones; L Donovan; J V Parry; O N Gill
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.

Authors:  J Lorvick; A H Kral; K Seal; L Gee; B R Edlin
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

3.  Health effects of prisons. Many injectors stop injecting while imprisoned.

Authors:  B P Smyth
Journal:  BMJ       Date:  2000-12-02

4.  Minimising harm from hepatitis C virus needs better strategies.

Authors:  N Crofts; S Caruana; S Bowden; M Kerger
Journal:  BMJ       Date:  2000-10-07

Review 5.  Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.

Authors:  Enrique R Pouget; Holly Hagan; Don C Des Jarlais
Journal:  Addiction       Date:  2012-04-17       Impact factor: 6.526

Review 6.  Updating the infection risk reduction hierarchy: preventing transition into injection.

Authors:  David Vlahov; Crystal M Fuller; Danielle C Ompad; Sandro Galea; Don C Des Jarlais
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

7.  Prisons as social determinants of hepatitis C virus and tuberculosis infections.

Authors:  Niyi Awofeso
Journal:  Public Health Rep       Date:  2010 Jul-Aug       Impact factor: 2.792

8.  Increased access to unrestricted pharmacy sales of syringes in Seattle-King County, Washington: structural and individual-level changes, 1996 versus 2003.

Authors:  Ryan J Deibert; Gary Goldbaum; Theodore R Parker; Holly Hagan; Robert Marks; Michael Hanrahan; Hanne Thiede
Journal:  Am J Public Health       Date:  2006-06-29       Impact factor: 9.308

9.  HIV and hepatitis C among injecting drug users.

Authors:  R A Coutinho
Journal:  BMJ       Date:  1998-08-15

10.  Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.

Authors:  Charlotte H S B van den Berg; Colette Smit; Margreet Bakker; Ronald B Geskus; Ben Berkhout; Suzanne Jurriaans; Roel A Coutinho; Katja C Wolthers; Maria Prins
Journal:  Eur J Epidemiol       Date:  2007-03-03       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.